SRX Cardio, LLC

Patent Applications and Registrations

Patent applications and USPTO patent grants for SRX Cardio, LLC.The latest application filed is for "compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (pcsk9)".

Company Profile

12.16.13

SRX Cardio, LLC - Pittsford NY US
SRX CARDIO, LLC. - Pittsford NY US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Compounds For The Modulation Of Proprotein Convertase Subtilisin/kexin Type 9 (pcsk9) App 20220267269 - Bowers; Simeon ; et al.	2022-08-25
Compounds For The Modulation Of Proprotein Convertase Subtilisin/kexin Type 9 (pcsk9) App 20220193058 - Bowers; Simeon ; et al.	2022-06-23
Composition And Methods Of Use Of Tetrahydroisoquinoline Small Molecules To Bind And Modulate Pcsk9 Protein Activity App 20210309613 - Barta; Thomas E. ; et al.	2021-10-07
Method To Treat Lipid Dysregulation By Modulation Of Proprotein Convertase Subtilisin/kexin Type 9 (pcsk9) Protein Activity With Small Molecule Ligands App 20210275551 - Barta; Thomas E. ; et al.	2021-09-09
Composition And Methods Of Use Of Novel Phenylalanine Small Organic Compounds To Directly Modulate Pcsk9 Protein Activity App 20210236481 - Barta; Thomas E. ; et al.	2021-08-05
Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands Grant 11,026,957 - Barta , et al. June 8, 2	2021-06-08
Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use Grant 10,980,801 - Barta , et al. April 20, 2	2021-04-20
Compounds For Binding Proprotein Convertase Subtilisin/kexin Type 9 App 20210032214 - Pandey; Anjali ; et al.	2021-02-04
Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity Grant 10,865,185 - Barta , et al. December 15, 2	2020-12-15
Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity Grant 10,821,106 - Barta , et al. November 3, 2	2020-11-03
Phenylpiperazine Proprotein Convertase Subtilisin/kexin Type 9 (pcsk9) Modulators And Their Use App 20200253958 - Kind Code	2020-08-13
Method To Treat Hypercholesterolemia By Modulation Of Proprotein Convertase Subtilisin/kexin Type 9 (pcsk9) Protein Activity Wit App 20200253995 - Kind Code	2020-08-13
Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity Grant 10,688,114 - Barta , et al.	2020-06-23
Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use Grant 10,568,882 - Barta , et al. Feb	2020-02-25
Composition and Methods of Use of Small Molecules as Binding Ligands for the Modulation of Proprotein Convertase Subtilisin/Kexi App 20190358248 - Barta; Thomas E ; et al.	2019-11-28
Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity Grant 10,307,433 - Barta , et al.	2019-06-04
Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels Grant 10,287,317 - Muehlemann , et al.	2019-05-14
Composition And Methods Of Use Of Small Molecules As Binding Ligands For The Modulation Of Proprotein Convertase Subtilisin/kexin Type 9(pcsk9) Protein Activity App 20180303855 - Barta; Thomas E. ; et al.	2018-10-25
Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity Grant 10,034,892 - Barta , et al. July 31, 2	2018-07-31
Composition And Methods Of Use Of Small Molecules As Binding Ligands For The Modulation Of Proprotein Convertase Subtilisin/kexin Type 9(pcsk9) Protein Activity App 20170246196 - Barta; Thomas E. ; et al.	2017-08-31
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Allosteric Binding Ligands To Modulate Serum Low Density Lipoprotein (LDL) Levels App 20160083425 - Muehlemann; Michael M. ; et al.	2016-03-24

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.